Phaseline

Companies › SinoMab BioScience

SinoMab BioScience: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SM17
monoclonal antibody
–Phase 2Atopic DermatitisApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07445919SM17Phase 2Atopic DermatitisImmunologyApr 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Bluefin Biomedicine Elixiron Immunotherapeutics (Hong Kong) Aravax VivaTech International AltruBio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.